Pharmaceutical

UCB to divest China neurology and allergy business for $680m

UCB has entered a divestment agreement in China to sell its mature neurology and allergy business to CBC Group and Mubadala for $680m.

Aug 27, 2024 - 04:00
UCB to divest China neurology and allergy business for $680m
UCB has entered a divestment agreement in China to sell its mature neurology and allergy business to CBC Group and Mubadala for $680m.
Read the original article

Tags:

Previous Article

Key discovery by Duke-NUS advances fight to reduce breast cancer recurrence

Next Article

MSD snags European approval for pulmonary arterial hypertension therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Lisata clinches rare disease status for osteosarcoma drug

Lisata clinches rare disease status for osteosarcoma drug

Mar 24, 2024

CMS proposes new pathway for reimbursing breakthrough devices

CMS proposes new pathway for reimbursing breakthrough d...

Jun 22, 2023

Delta 8 THC use reported by 11% of high school seniors

Delta 8 THC use reported by 11% of high school seniors

Mar 13, 2024